stem cell companies closing the valuation gap., page-2

http://www.economist.com/blogs/babbage/2012/10/nobel-prize-physiology-or-medicine

Another brilliant read. Digger is that you 20th post down?

"Steven, See my comments below (Diggerby) and look at the share price performance of ASX: MSB (Mesoblast) since 2004 and you might find others that have already gone way down the path here. I suggest you Google Companies such as Osiris, Aastrom, and Cynata . Regenerative therapeutics, especially allegeneic , off-the-shelf treatments, represent a new paradigm for Biopharma. This is a compelling opportunity for investors, and I daresay patients in need of affordable, effective regenerative treatment. (eg: complication of diabetes - eg CLI and Ulceration; Heart attack, spinal disk repair and many other conditions). Investing in Biotech is risky, only put in money that you can afford to lose but the upsides are potentially huge."